Schedule of Events
Thursday, April 24, 2014
8:45AM - 9:45AM
CPhA's Leadership Development Institute Project
A yearlong leader development program sponsored by CPhA consisting of four in-person sessions, with individual and small group work performed between sessions. As a professional association CPhA largely depends on talent existent in its volunteers. Consequently, investment in volunteer development is critical for ensuring CPhA’s future success. To facilitate meaningful, lasting change, this program applies structure between the live learning sessions, which are designed to stimulate the participant’s application of the philosophies, strategies and tactics in their daily lives. Structure includes a personal development plan, a project, and a small peer group led by more experienced “mentors” and advanced participants.
At the completion of this activity, the participant will be able to: 1.Describe the “what, why and how” of the LDI program as it relates to CPhA and your current goals 2.Discuss and assess leadership in volunteer organizations 3.Clarify and define the four critical conversations for effective leadership to be utilized in future leadership roles 4.Transform destructive “victims” into productive “players” 5.Explain a leader’s role in creating opportunities for members to experience flow
Clifford Young, RPh, University of the Pacific
Michael Conner, PharmD, Target
Annie Ho, PharmD, Kern Medical Center
Johanna Liu, PharmD, Health Net
Oby Stan-Ugbene, PharmD, University of the Pacific
An update on CMS Medicaid Drug pricing initiatives National Average Drug Acquisition Cost and Federal Upper Limits
The Centers for Medicare and Medicaid Services undertook a review of Drug Cost at the request of several state Medicaid programs and has established a new drug pricing benchmark. That new drug reference price is now being supplied to the state Medicaid agencies and being published by the major drug pricing compendium. The intent of this program is to provide the attendee with a basic understanding of how this has impacted pharmacy payments in other states and the potential impact in California for the Medi-Cal fee-for-service program. The session will address current guidance and what requirements states have been given for changes to the fee-for-service drug payment system. Also what are other potential impacts on the utilization of branded and generic products.
At the completion of this activity, the participant will be able to: 1. Understand what the basis is and the calculation of the National Average Drug Acquisition Cost (NADAC). 2. Have a basic understanding of the Average Manufacturer Price and Weighted Average Manufacturer Price calculation and differences. 3. Have a basic understanding of the Federal Upper Limit (FUL) Calculation. 4. Have a basic understanding of how Pharmacy reimbursement is reviewed by the Centers for Medicare and Medicaid Services when they receive a state plan amendment to change reimbursement.
Doug Hillblom, PharmD, OPTUMRx
10:00AM - 12:00PM
Pharmacy Transition: Strategies and Tactics for Buyers and Sellers
Sponsored by Cardinal Health
You will learn how to value a community pharmacy, market your pharmacy to buyers, how to structure financing and financing requirements, determine which pharmacies are for sale, and when to engage professional attorneys, accountants and others.
At the completion of this activity, the participant will be able to: 1. Valuing a pharmacy 2. Analyzing the financial health of a pharmacy 3. Structuring the financing of your purchase or sale 4. Determine which factors impact the valuation of a pharmacy 5. Consider Key Performance Indicators of community pharmacy
Jimmy Neil, MBA, Cardinal Health
Recognizing Mental Health Issues: Prevention Gatekeeper Training
Pharmacists are regarded as one of the most trusted and accessible healthcare professionals and they have the potential to dramatically impact patients’ lives on a daily basis. Currently, there is no published education/training program that has targeted pharmacists to increase awareness of and prevent suicides. We have partnered with CHIP, the SD Suicide Prevention Council and SDPharmNet, a pharmacist practice-based research network, to disseminate and evaluate a suicide prevention program for pharmacists.
At the completion of this activity, the participant will be able to: 1. Understand the prevalence of Suicide in the US and in San Diego 2. Dispel myths about Suicide 3. Identify actions and words that indicate thoughts of suicide might be present 4. Learn the simple three step process you can use to save a life 5. Identify some local resources that can help
Nathan Painter, PharmD, CDE, University of California, San Diego
Stan P. Collins, B.A., University of California, San Diego
12:45PM - 1:45PM
Precepting Students - What's in it for you?
There may be misconceptions regarding precepting pharmacy students such as it takes too much time, there are no benefits, etc. This program is intended to make precepting fun, educational, informative, and, beneficial to the preceptor and the organization.
Glenn Yokoyama, PharmD, UCSF, School of Pharmacy
Pharmacists Ordering Lab Tests
Sponsored by Cardinal Health
With SB493 signed into law, the statutes allow pharmacists the ability to order lab tests. This session will review the process in which the pharmacist can order lab test and how to interpret the information.
Steven Chen, PharmD, University of Southern California
2:00PM - 4:00PM
Compliance with State and Federal Requirements in Long Term Care
The program will provide an overview of federal and state regulatory issues affecting residents in long-term care facilities. It will focus on unnecessary drug as related to antipsychotic medications and CMS initiative for managing residents with dementia and reduction of antipsychotic use. The survey tool used by CDPH surveyors to evaluate compliance with state and federal requirements including informed consent.
At the completion of this activity, the participant will be able to: 1. Become familiar with State and Federal regulations for Pharmaceutical Services 2. Identify CMS target goal for antipsychotic medication use in skilled nursing facilities. 3.Understand CDPH “Antipsychotic Use Survey Tool” 4.Discuss elements of SNF informed consent for antipsychotic medications. 5.Identify who can obtain informed consent for antipsychotic medications
Sue Chaban, PharmD, CDPH, Center for Health Care Quality Licensing and Certification Program
Center for Health Care Quality, Licensing and Certification program
Design MTM Services for Patients with Digestive and Liver Disorders
There are many opportunities for pharmacists to utilize MTM services in community/ambulatory care settings. More than 95 million Americans experience some kind of digestive problem, opens a door to provide MTM services in this area. Implementation of these services requires acquiring the knowledge and applying this knowledge to the practice. This course will assist pharmacists to enhance the skills to offer these services in their respective practice settings
At the completion of this activity, the participant will be able to: 1.Describe potential opportunities to implement MTM services in digestive disorders 2.List different assessment tools that can be utilized in the implementation of MTM services in the digestive disorders 3.Create a business plan for initiating MTM services in the digestive disorders 4.Describe potential opportunities and challenges in implementing these services
Hyma Gogineni, MSc, PharmD, TTS, BCACP, Western University of Health Science
4:15PM - 5:45PM
2014 New Pharmacy Laws Update
Sponsored by California Pharmacy Lawyers
This program will review and summarize all new laws pertaining to the practice of pharmacy in California, emphasizing those with potentially far-reaching impact, and examining their real world effects.
At the completion of this activity, the participant will be able to: : 1. Recognize all new pharmacy laws in California. 2. Distinguish between old and new rules of pharmacy practice. 3. Identify potential pitfalls caused by the new pharmacy laws. 4. Construct a pharmacy action plan to ensure conformity with all new laws.
Tony Park, PharmD, J.D., California Pharmacy Lawyers
UAN: 0113-0000-14-577-L04-PThis session will review the FDA-approved, first-line smoking cessation medications, with an emphasis on nicotine replacement therapy products. A case-based approach will be used to understand the role of pharmacotherapy in helping a person quit smoking, including combination therapy. The statewide nicotine replacement therapy protocol developed for the new SB493 authority will be discussed.
At the completion of this activity, the participant will be able to: 1. List the FDA-approved first-line smoking cessation medications and describe their dosing, side effects, and precautions/contraindications. 2. Based on patient specific characteristics, develop an appropriate starting regimen for nicotine replacement therapy. 3. Describe brief smoking cessation counseling interventions that promote referrals to local resources for additional counseling and support.
Lisa Kroon, PharmD, UC San Francisco, School of Pharmacy
Robin Corelli, PharmD, UC San Francisco, School of Pharmacy